sexual-health
PT-141
A centrally acting melanocortin-4 receptor agonist (bremelanotide) that activates hypothalamic arousal pathways through dopaminergic and oxytocinergic signaling — mechanistically distinct from peripheral vasodilator approaches.
For research and laboratory use only. Not for human consumption.
Subscribe & save: $166
Quantity
Add 1 more to save 10% per unit
Technical Data
Specifications
Technical Details
Bulk Pricing
Volume Pricing Guide
Quality Assurance
Certificate of Analysis
Certificate of Analysis
Research Overview
About PT-141
PT-141 (bremelanotide) is a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (α-MSH) that acts as a selective agonist at melanocortin receptors MC3R and MC4R in the central nervous system. Unlike phosphodiesterase-5 inhibitors that operate through peripheral vascular smooth muscle relaxation, PT-141's mechanism is fundamentally central — activating dopaminergic and oxytocinergic pathways within the hypothalamus that govern sexual motivation and arousal response.
Clinical research has been conducted across both male and female populations, with significant attention to hypoactive sexual desire disorder (HSDD) in women — a condition where the central, non-vascular mechanism offers theoretical advantages over peripherally acting agents. The compound's receptor selectivity profile was refined from its precursor Melanotan II through structural optimization to minimize off-target melanocortin effects.
ROEHN supplies PT-141 at 99% HPLC-verified purity as a lyophilized powder. It is available in both injectable and nasal spray formats, supporting research protocols investigating melanocortin receptor pharmacology, central arousal circuitry, and gender-inclusive sexual function endpoints.
